24/7 Market News Snapshot 07 January, 2025 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

January 7, 2025

DENVER, Colo., 07 January, 2025 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. (NASDAQ:HOTH) is currently witnessing significant momentum in the market as its share price surged to $1.787, reflecting an extraordinary increase of 118.03% from the previous close of $0.820. The pre-market trading volume has reached 14.86 million shares, underscoring the growing investor interest in the biotech firm. Technical analysis indicates a sustained upward trajectory, prompting analysts to focus on potential developments that may influence the company’s future performance.

Moreover, in a critical advancement for the company, Hoth Therapeutics has reported promising interim results from its Phase 2a clinical trial of HT-001, which targets skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi) used in oncology. The trial’s open-label segment, known as CLEER-001, demonstrated that 100% of participants achieved the primary efficacy goal of an Acneiform Rash Investigator Global Assessment (ARIGA) score of ≤1 within six weeks, highlighting a marked improvement in skin toxicity management. Additionally, 66% of patients noted relief from pain and itching, significantly enhancing their quality of life without any treatment-related adverse effects, enabling them to continue their full dosing of EGFRi medications.

Hoth Therapeutics’ CEO, Robb Knie, emphasized the significance of these results as a major step in improving patient care by potentially mitigating debilitating side effects that can hinder cancer treatments. The company has developed the proprietary ARIGA scale in collaboration with onco-dermatology experts, reinforcing the methodology used for measuring skin toxicity in this context.

As patient enrollment progresses, Hoth Therapeutics remains dedicated to validating these encouraging findings, aiming to position HT-001 as a new standard of care in the management of skin toxicities within cancer therapy. The industry keenly awaits further developments that may solidify Hoth’s role as an emerging leader in the biopharmaceutical landscape.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.